HEPATOLOGY Journal
@HEP_Journal
Followers
18,850
Following
492
Media
934
Statuses
3,859
HEPATOLOGY: Official journal of AASLD ( @AASLDtweets ) covering liver diseases, hepatitis, cancer, cirrhosis, drug metabolism, and immunology #AASLDJournals
Alexandria, VA
Joined October 2014
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Rio Grande do Sul
• 468826 Tweets
Magic
• 191404 Tweets
Galatasaray
• 145899 Tweets
Al Jazeera
• 130316 Tweets
#MiamiGP
• 114180 Tweets
Bernard Hill
• 110003 Tweets
Luciano
• 95885 Tweets
Cinco de Mayo
• 93584 Tweets
Perez
• 78853 Tweets
Menotti
• 76285 Tweets
LISA TEAM REDBULL
• 75813 Tweets
Spurs
• 70447 Tweets
Tottenham
• 68925 Tweets
BBL Drizzy
• 58856 Tweets
Cavs
• 52803 Tweets
Ziyech
• 42771 Tweets
Verstappen
• 37636 Tweets
#محمد_عبده
• 30903 Tweets
Velez
• 29831 Tweets
Leclerc
• 28978 Tweets
Paolo
• 26893 Tweets
Garland
• 25266 Tweets
Cleveland
• 24304 Tweets
Bülent Uygun
• 19806 Tweets
Checo
• 19064 Tweets
Franz
• 18855 Tweets
McLaren
• 18603 Tweets
Sainz
• 14975 Tweets
Icardi
• 12250 Tweets
Donovan Mitchell
• 11724 Tweets
Nestor
• 10341 Tweets
NEW PRACTICE GUIDANCE!
Singal A et al.
@AASLDtweets
Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
#LiverTwitter
1
92
220
REVIEW
Controversies regarding albumin therapy in cirrhosis
#JonelTrebicka
@ggarciatsao
#LiverTwitter
0
57
154
REVIEW: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC
Suzanne Sharpton &
@DrLoomba
#LiverTwitter
0
48
148
🚨
@AASLDtweets
Practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis 🚨 JUST RELEASED
#LiverTwitter
#LiverX
0
70
147
Just released! Don't miss it! New
#MASLDNomenclature
! by
@AASLDtweets
at
@Hep_Journal
: [] in a joint publication with
@alehlatam
@EASLnews
#LiverTwitter
0
73
128
REVIEW
Obesity management for the hepatologist—What to do, how to do it and why?
by
@kymwatt
@mqkMD
et al.
#LiverTwitter
1
50
128
February
@HEP_Journal
: Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
@sapisochin
#TommyIvanics
@JulieHeimbach
#LiverTwitter
2
45
96
REVIEW: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management
Allaire M & Thabut D.
#LiverTwitter
2
46
96
REVIEW:
Mehta N et al. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies.
#LiverTwitter
0
36
82
REVIEW: Checkpoint inhibitor hepatotoxicity: pathogenesis and management
Cunningham M; Gupta R; Butler M.
#LiverTwitter
1
29
81
🚨
@AASLDtweets
Guía práctica sobre la estratificación del riesgo y el manejo de la hipertensión portal y las várices en la cirrosis 🚨 RECIÉN PUBLICADO
#LiverTwitter
#LiverX
0
26
76
This month in
@HEP_Journal
Introducing Norah Terrault, MD, MPH, Our 2023
@AASLDPresident
@AASLDtweets
@AASLDFoundation
#LiverTwitter
3
15
68
NEW PRACTICE GUIDANCE
A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases
#LiverTwitter
0
29
61
Great summary by
@BloomPringle
of her team’s recent publication on liver enzyme elevation in
#COVID19
patients
@AASLDtweets
0
11
54
#HEP_highlights
: This new score for at-risk MASH is absolutely MASEF!
The serum-based Metabolomics-Advanced Steatohepatitis Fibrosis (MASEF) score can accurately identify MASH with ≥F2 fibrosis
#LiverTwitter
@NoureddinMD
2
18
50
⭐️HOT OFF THE PRESS⭐️
LEGACY study evaluating response of 90Y glass microspheres for solitary unresectable
#HCC
↪️88.3% response rate
��️62.2% with response for at least 6 months
↪️86.6% 3yr survival
@bostonsci
@AASLDtweets
@riadsalemIR
#livertwitter
👉🏼
0
29
48
REVIEW ARTICLE: Shah PA et al. NAFLD-related hepatocellular carcinoma: The growing challenge
#LiverTwitter
1
20
46
PRACTICE GUIDANCE
Schilsky M et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
#LiverTwitter
1
15
45
#Aspirin
use and risk of
#HCC
in patients with chronic
#hepatitisB
with or without
#cirrhosis
✅Associated with ⬇️ risks of HCC and liver-associated mortality in adults with CHB
✅Cirrhosis status had a substantial effect
#LiverTwitter
3
20
44
#HEP_Highlights
A Right way to TIPS
Bommena S et al. The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study
#LiverTwitter
0
21
43
Huang DQ, Tran A et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase
#LiverTwitter
1
19
43
NEW
@AASLDtweets
Practice Guidance! on the clinical assessment and management of nonalcoholic fatty liver disease
#NAFLD
#LiverTwitter
@marurinella
@Mayo_liverdoc
@DrLoomba
0
20
42
#HEP_highlights
: Refractory Hepatic Hydrothorax: An Ominous Sign of End-Stage Liver Disease
Chin A et al. Refractory HH is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites
#LiverTwitter
0
19
42
El Hajra I et al. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
#LiverTwitter
0
19
39
Edeline J et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials
#LiverTwitter
0
14
40
Younossi ZM et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
#LiverTwitter
0
13
41
REVIEW
Zanuso V et al. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy.
#LiverTwitter
0
10
41
NEW PRACTICE GUIDANCE:
Bowlus CL et al.
@AASLDtweets
practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
#LiverTwitter
0
21
40
Díaz-González Á et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
#LiverTwitter
1
25
38
ABIDE score predicts decompensation in
#NAFLD
#cirrhosis
✳️ Uses AST/ALT ratio, bilirubin, INR, DM2, and esophageal varices
✳️ Model constructed and validated in patients with bx proven cirrhosis
✳️ 5y accuracy better than other markers including CTP, MELD
0
23
39
NUEVA GUÍA DE PRÁCTICA CLÍNICA
Un enfoque multidisciplinario para el diagnóstico y tratamiento de la enfermedad de Wilson: Guía práctica de 2022 sobre la enfermedad de Wilson de la AASLD
#LiverTwitter
1
10
37
We have a new website!
Please visit and subscribe for eTOCs!
@hmalhi
@juanpabloarab
@SumeraIlyasMD
@AASLDtweets
#MedTwitter
#GITwitter
#LiverTwitter
0
20
37
Lv Y et al. Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding
#LiverTwitter
0
19
36
Also currently the Editor of our journal...Congrats to Dr. David Cohen!
@AASLDtweets
Congratulations to Dr. David Cohen,
#BrighamGIAlum
, our former Dir. of Hepatology & current Chief of
@WCM_GI
, for his election to the prestigious Association of American Physicians!
Dr. Cohen is a leader in studying the molecular regulation of hepatic lipid & glucose metabolism.
0
1
15
4
4
36
Nicoară-Farcău O et al.
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis
#LiverTwitter
0
14
36
Excited to have Dr. Gores as our next Editor in Chief!
#livertwitter
Breaking News!
Join us in congratulating Gregory Gores, MD, FAASLD, who will be the next editor in chief for AASLD's flagship journal,
@HEP_Journal
in January 2022. Great things are happening at
#AASLD
!
#TLMdX
#LiverTwitter
@MayoClinic
@MayoClinicGIHep
18
22
204
0
1
36
Introducing Laurie DeLeve, M.D., Ph.D., Our 2022
@AASLDPresident
by Neil Kaplowitz
#LiverTwitter
0
10
35
¡NUEVA GUÍA DE PRÁCTICA!
Singal A et al.
@AASLDtweets
Guía práctica sobre prevención, diagnóstico y tratamiento del carcinoma hepatocelular
#LiverTwitter
0
11
35
REVISIÓN:
Controversias sobre la terapia con albúmina en la cirrosis
#JonelTrebicka
@ggarciatsao
#LiverTwitter
0
13
35
@AASLDtweets
Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage
Lee EW et al.
#livertwitter
0
11
35
Deltenre P et al. The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions
#LiverTwitter
0
12
35
1
28
34
REVIEW:
@renumathyd
et al. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
#LiverTwitter
@HoshidaYujin
0
12
33
MELD eliminates racial disparities once on the waitlist for liver
#transplant
but
@rrosenblattmd
et al show that Black patients still face a
#disparity
in terms of access to transplant listing
⭐️This is a must read:
@AASLDtweets
#livertwitter
0
8
33
Improved prediction of waitlist mortality by replacing Cr with eGFR in MELD-Na
0
11
33
Preliminary evidence of safety and tolerability of
#atezolizumab
plus
#bevacizumab
in patients with
#HCC
and Child-Pugh A and B cirrhosis: A real-world study
#LiverTwitter
0
7
32
Response to
#terlipressin
+
#albumin
is associated with improved
#liver
#transplant
outcomes in
#HRS
- better 30 day transplant free survival
- ⬇️ MELD at LT
- ⬇️ renal replacement therapy post LT
- ⬇️
#CKD
1 year post LT
Read it today👉🏼
#livertwitter
0
11
31
Access the newest practice
#guidance
available from
@AASLDtweets
:
#Palliative
care and symptom-based management in decompensated
#cirrhosis
.
#LiverTwitter
@ArpanPatelMD
@NnekaUfereMD
@KanwalFasiha
1
9
31
Biliary SCT/SCTR/miR-125b axis regulation of biliary damage, hepatic steatosis, and fibrosis in NAFLD/NASH
FULL ARTICLE:
0
10
29
#HEP_Highlights
But maybe the AlcHep will recompensate… or not?
✅ Hsu C et al. Multi-Centered Study of Patient Outcomes after Declined for Early Liver Transplantation in Severe Alcohol-Associated Hepatitis
#LiverTwitter
0
16
30
Berardi G et al. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome
#LiverTwitter
1
16
30
Liver
#transplantation
outcomes in patients with
#HCC
presenting beyond Milan Criteria from the US Multicenter HCC Transplant Consortium
0
12
30
SPECIAL ARTICLE: Neil DAH et al. Banff consensus recommendations for steatosis assessment in donor livers
#LiverTwitter
0
17
29
0
10
28
Lv Y et al. Concurrent large spontaneous
#portosystemic
shunt embolization for the prevention of overt hepatic
#encephalopathy
after
#TIPS
: A randomized controlled trial
#LiverTwitter
0
11
29
Campani C et al. Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab
#LiverTwitter
0
11
28
New synthetic
#UDCA
derivatives that exert selective HDAC6 activity and improves
#polycystic
liver disease pathogenesis
0
5
27
Kim BK et al. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
#LiverTwitter
2
11
28
Levy C et al. Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
#LiverTwitter
@DrCynthiaLevy
0
7
27
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
#WorldHepatitisDay
@AASLD
0
22
26
Corpechot C et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
#LiverTwitter
0
9
26
Este mes en
@HEP_Journal
presentamos a Norah Terrault, MD, MPH, Nuestra 2023
@AASLDPresident
@AASLDtweets
@AASLDFoundation
#LiverTwitter
1
5
27
Hepatitis B cure: From discovery to regulatory approval- Free article until September
#WorldHepatitisDay
@AASLDtweets
0
19
27
REVIEW‼️
McConnell MJ, Kostallari E, Ibrahim S, Iwakiri Y.
The evolving role of liver sinusoidal endothelial cells in liver health and disease
0
6
27
@AASLDtweets
Guía práctica sobre el uso de TIPS, embolización de várices y obliteración transvenosa retrógrada en el tratamiento de la hemorragia de várices
Lee EW et al.
#livertwitter
0
4
27
Younossi ZM et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
#LiverTwitter
0
12
25
Transcriptional dynamics of hepatic sinusoid‐associated cells after liver injury
0
9
25
REVISIÓN
Manejo de la obesidad para el hepatólogo: ¿Qué hacer, cómo hacerlo y por qué?
por
@kymwatt
@mqkMD
et al.
#LiverTwitter
0
7
25
Nabi O et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)
#LiverTwitter
0
13
25
D’Amico G et al. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements.
#LiverTwitter
0
11
25
Important read for all involved in the care of liver patients!
AASLD expert panel publishes a consensus statement on best practice for hepatologists during
#Covid_19
0
7
23
Re-highlighting this article - we are publishing more and more
#NAFLD
research and this helps standardize the process
#livertwitter
@AASLDtweets
@HannesHagstrom
👉🏼
1
9
25
#HEP_highlights
Itching for Improvement- New Treatment Option for Primary Biliary Cholangitis
🚨Pts w/PBC with inadequate resp or intolerance to UDCA treated with seladelpar 10 mg had significant improve in liver biochemistry and pruritus.
#livertwitter
3
14
25
#Mitochondrial
bioenergetics boost
#macrophage
activation, promoting liver
#regeneration
in
#metabolically
compromised animals
#LiverTwitter
0
7
24
Genome-wide association study and meta-analysis identifies genetic variants that underlie risk for
#alcohol
-related
#cirrhosis
- see the author’s summary below!
0
8
25
REVIEW: Alcohol use disorder in community management of chronic liver diseases
@Lorenzo__Leggio
and
#JessicaMellinger
#LiverTwitter
1
8
25
February
@HEP_Journal
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Scott L.
#Friedman
& Massimo
#Pinzani
#LiverTwitter
0
10
24
#HEP_highlights
May:
Sanyal A et al. study, based on two large placebo-controlled trials demonstrated that
#regression
of
#NAFLD
cirrhosis is associated with a lower risk of liver-related clinical events
#LiverTwitter
1
11
23
Lockart I at al.
#HCC
incidence after
#hepatitis
C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis
#LiverTwitter
0
14
23
Tan DJH et al. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH
#LiverTwitter
1
13
24
The global burden of liver cancer and
#cirrhosis
has increased from 2012 to 2017 with
#NAFLD
growing as a contributor to liver related morbidity and mortality
1
17
24
Younossi ZM et al. La epidemiología mundial de la enfermedad del hígado graso no alcohólico (NAFLD) y la esteatohepatitis no alcohólica (NASH): una revisión sistemática
#LiverTwitter
0
10
23
Important review on addressing
#NAFLD
in important populations where there can be benefits, impact on future generations and those at high risk for progression
🔑Children and adolescents
🔑Future parents
🔑Postmenopausal women
0
11
23
REVIEW: Singal A et al. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease
@l_suthat
@mandrekp
@norahterrault
@Dr_Vijay_Shah
@juanpabloarab
@WRayKimMD
#LiverTwitter
0
16
23
REVIEW‼️
Friedman S & Sanyal A.
The future of hepatology:
✅Basic and translational science
✅Data management
✅Artificial intelligence
✅Precision medicine
0
6
23
How cool is our December issue cover?! 🤩
We encourage authors to submit original artwork for the journal cover. Congratulations to the authors of our December cover article
#LiverTwitter
@hmalhi
@SumeraIlyasMD
0
9
23
Actionable items for reducing the burden of
#alcohol
associated
#liver
disease by
@AsraniSumeet
et al
🔅Improve data, standardize care
🔅Innovative healthcare delivery platforms
🔅Increase
#advocacy
by professional organizations
🔅Digital interventions
0
8
23
#HEP_highlights
Etiological Treatment of Decompensated Cirrhosis: Is It Worthwhile?
Tonon L, Balcar L et al. In patients with cirrhosis and ascites as single first decompensating event, the cure of liver disease etiology represents a main treatment goal
0
9
22
HEP_Highlights: Short Telomeres, Big Questions
Gellert-Kristensen H et al. Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
#LiverTwitter
0
6
23
#HEP_highlights
January: A picture is worth a thousand words - MRE in NAFLD
Serial MREs used to measure longitudinal liver stiffness show promise in predicting disease progression and liver-related outcomes in pts with NAFLD
@AlinaAllenMD
#livertwitter
0
9
23
@AASLDtweets
Practice Guidance:
#Palliative
care and symptom-based management in decompensated
#cirrhosis
@ArpanPatelMD
@NnekaUfereMD
@KanwalFasiha
#LiverTwitter
0
13
23
#HEP_highlights
To Treat, or Not to Treat
Huang DQ et al. Among pts with compensated cirrhosis and serum HBV-DNA levels 20-2000 IU/mL, treatment with antiviral therapy does not lead to ⬇️ rates of hepatic decompensation or HCC
#LiverTwitter
0
10
23
HEP_highlights November: Precision genomics for unexplained ALT elevation
Alonso-Peña M et al. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
#LiverTwitter
1
14
22
#HEP_Highlights
January: Detection of
#cholangiocarcinoma
in pts with
#PSC
is incredibly challenging. Vedeld et al. identified DNA methylation biomarkers that detected CCA up to 12 months prior to conventional CCA detection modalities.
#LiverTwitter
0
7
21